^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG:

methotrexate

Company:
Generic mfg.
Drug class:
THF dehydrogenase inhibitor, Dihydrofolic acid reductase inhibitor
4d
Pediatric Primary Cutaneous CD8+ Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma With Unusually Long Clinical Course. (PubMed, J Cutan Pathol)
Despite partial responses to topical therapies, oral prednisone, and methotrexate, the disease persisted, highlighting therapeutic challenges. This case underscores the importance of molecular profiling in PCAECTCL and suggests potential utility for JAK inhibitors like ruxolitinib.
Journal
|
JAK2 (Janus kinase 2) • CD8 (cluster of differentiation 8) • CD5 (CD5 Molecule) • GZMB (Granzyme B) • PCM1 (Pericentriolar Material 1) • CD2 (CD2 Molecule)
|
Jakafi (ruxolitinib) • methotrexate • prednisone
4d
Apremilast ameliorates methotrexate-induced renal injury in rats: role of TLR4/NF-κB/P38 MAPK/caspase-3 and Nrf2/HO-1 signaling pathways. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
Co-treatment with APRE at 20 mg/kg/day for 21 days markedly improved all biochemical and pathological alterations evoked by MTX, demonstrating significant nephroprotective effects. Apremilast inhibits methotrexate's harmful effects on the kidneys by activating signaling cascades that include Nrf2/HO-1, while simultaneously downregulating TLR4/NF-κB/p38 MAPK/Caspase-3.
Preclinical • Journal • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • HMOX1 (Heme Oxygenase 1) • CASP3 (Caspase 3) • TLR4 (Toll Like Receptor 4) • RELA (RELA Proto-Oncogene)
|
methotrexate
4d
Tumor cell-derived microparticles induced by methotrexate reprogram neutrophil antitumor response via lysosomal ROS mediated degranulation. (PubMed, Mol Cancer Res)
By performing the combination of MTX-MP-activated neutrophils and OT-1 CD8+ T cells transfer, we found that the long-term survival rate improved in OVA-expressing Lewis lung carcinoma (LLC-OVA) models. Implications: Our findings revealed a new way by which activated-neutrophils release microparticles to kill tumor cells and provided a potential combinatorial therapeutic strategy for tumor immunotherapy.
Journal
|
CD8 (cluster of differentiation 8)
|
methotrexate
4d
Successful treatment of primary intramedullary spinal cord lymphoma based on the molecular diagnosis of a MYD88 mutation in the cerebrospinal fluid: a case report. (PubMed, Int Cancer Conf J)
Treatment with rituximab, high-dose methotrexate, and focal radiotherapy was initiated...Liquid biopsy of the CSF provides a promising alternative for diagnosing PISCL. However, further studies are needed to validate the clinical utility of this diagnostic approach.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL2 (Interleukin 2) • IL10 (Interleukin 10)
|
Rituxan (rituximab) • methotrexate • methotrexate IV
4d
DDR1 as a key prognostic biomarker in non-small cell lung cancer: identification, validation, and potential therapeutic implications. (PubMed, Front Immunol)
Drug sensitivity analysis revealed that high DDR1 expression was associated with reduced sensitivity to methotrexate but increased sensitivity to vinblastine, doxorubicin, cisplatin, and docetaxel, with no significant difference observed for gefitinib. IHC of clinical samples confirmed DDR1 overexpression in 55.88% of NSCLC patients. Our study demonstrated that DDR1 promotes tumor progression and immune evasion and is frequently overexpressed in NSCLC patients, suggesting that DDR1 is a potential prognostic biomarker and therapeutic target.
Retrospective data • Journal • IO biomarker
|
DKK1 (dickkopf WNT signaling pathway inhibitor 1)
|
cisplatin • gefitinib • docetaxel • doxorubicin hydrochloride • methotrexate • vinblastine
4d
Cellular and humoral vaccination response under immunotherapies-German consensus on vaccination strategies in neurological autoimmune diseases. (PubMed, Ther Adv Neurol Disord)
The specific humoral and cellular response to vaccination can be compromised under alemtuzumab, azathioprine, cladribine, cyclophosphamide, CD19/CD20 antibodies (inebilizumab, ocrelizumab, ofatumumab, rituximab, ublituximab), dimethyl fumarate/diroximel fumarate, FcRn inhibitors (efgartigimod, rozanolixizumab), complement C5 inhibitors (eculizumab, ravulizumab, zilucoplan), interleukin-6 receptor antibodies (tocilizumab, satralizumab), intravenous immunoglobulins, long-term steroid administration, methotrexate, mitoxantrone, mycophenolate mofetil, tacrolimus, teriflunomide, tumor necrosis factor-α blockers, and sphingosine-1-phosphate receptor modulators (fingolimod, ozanimod, ponesimod, siponimod), as well as after autologous stem cell transplantation...However, the humoral and cellular vaccination response may be impaired under immunotherapy necessitating close monitoring. Here, we provide applicable recommendations to optimize immunization for individuals receiving immunotherapy due to a neurological autoimmune disease.
Journal
|
IL6R (Interleukin 6 receptor)
|
Rituxan (rituximab) • cyclophosphamide • methotrexate • Campath (alemtuzumab) • mitoxantrone • cladribine • Arzerra (ofatumumab) • Briumvi (ublituximab-xiiy) • fingolimod • Actemra IV (tocilizumab) • Ocrevus (ocrelizumab) • Uplizna (inebilizumab-cdon)
4d
Mixed-Phenotype Acute Leukemia Transforming Into Acute Myelomonocytic Leukemia (AML M4): A Case Report and Therapeutic Challenges. (PubMed, Cureus)
Hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) induction achieved morphological complete remission, but measurable residual disease (MRD) persisted. Consolidation with mini-cyclophosphamide, vincristine, and dexamethasone (mini-CVD) and prednisone, vincristine, methotrexate, and 6-mercaptopurine (POMP) maintenance failed to eradicate MRD, and overt relapse occurred at month 7. Nelarabine salvage was initiated...Early molecular risk stratification and deployment of targeted agents, venetoclax-based combinations, or timely allogeneic transplantation should be considered before irreversible genomic complexity emerges. Prospective studies tailored to high-risk cytogenetic subsets of MPAL are urgently needed.
Journal
|
IDH2 (Isocitrate Dehydrogenase (NADP(+)) 2)
|
Venclexta (venetoclax) • doxorubicin hydrochloride • cyclophosphamide • methotrexate • vincristine • prednisone • nelarabine • mercaptopurine
7d
Hesperidin methyl chalcone alleviates imiquimod-induced psoriasis in mice: effects alone and in combination with methotrexate. (PubMed, Naunyn Schmiedebergs Arch Pharmacol)
In conclusion, this study provides the first preclinical evidence that HMC, particularly in combination with MTX, ameliorates IMQ-induced psoriasis via modulation of inflammatory cytokines, oxidative stress, and histopathological damage. These findings suggest its potential as a therapeutic candidate that warrants further preclinical and clinical investigation in plaque-type psoriasis.
Preclinical • Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • IL17A (Interleukin 17A)
|
methotrexate • Zyclara (imiquimod)
7d
The "Route Cause" of Methotrexate-Induced Brain Structure Changes in a Juvenile Mouse Model: Comparison of Systemic and CNS-Targeted Chemotherapy. (PubMed, Neurotoxicology)
Comparison of systemic and intrathecal delivery routes revealed that systemic MTX had a wider impact on brain morphology than did IT MTX treatment, particularly at clinically relevant doses of IT MTX. This finding provides important insight into the mechanisms that likely underlie MTX-induced neurotoxicity and focuses potential interventions on systemic toxicity.
Preclinical • Journal
|
TP63 (Tumor protein 63)
|
methotrexate
8d
BI26 More than skin deep: a case of eosinophilic fasciitis in a patient with relapsing-remitting multiple sclerosis. (PubMed, Br J Dermatol)
Her disease remains well controlled on methotrexate 15 mg once weekly. While the development of eosinophilic fasciitis in this case was presumed to be idiopathic, to our knowledge, this is the first case of eosinophilic fasciitis developing in the setting of long-term ocrelizumab use.
Journal
|
CRP (C-reactive protein)
|
methotrexate • Ocrevus (ocrelizumab)
8d
SG05 The use of oral methotrexate in a case of Ferguson-Smith syndrome. (PubMed, Br J Dermatol)
Despite 3 years of acitretin therapy, surgical excisions, imiquimod and repeated cryotherapy, the lesions remained poorly controlled. This case, along with her sister's experience, highlights oral methotrexate as a potential therapeutic option for refractory cases. Further studies are needed to explore its role in the management of this challenging condition.
Journal
|
TGFBR1 (Transforming Growth Factor Beta Receptor 1)
|
methotrexate • Zyclara (imiquimod)
8d
PA26 Folliculotropic mycosis fungoides with large cell transformation in an adolescent patient. (PubMed, Br J Dermatol)
He commenced first-line systemic therapy with methotrexate, but had no response. He was switched to brentuximab vedotin and has received eight cycles with partial response...Approach to mycosis fungoides in children: consensus-based recommendations. J Am Acad Dermatol 2024; 91: 1078-85).
Journal
|
CD8 (cluster of differentiation 8) • TNFRSF8 (TNF Receptor Superfamily Member 8) • CD4 (CD4 Molecule) • CD7 (CD7 Molecule) • SESN1 (Sestrin 1)
|
TNFRSF8 expression
|
methotrexate • Adcetris (brentuximab vedotin)